Current Research

36 Active Trials at 31 Institutions in 27 Diseases in 7 Countries

We support investigator-initiated repurposing research projects in any unsolved disease including cardio, neuro, oncology, ophthalmic, vascular and rare diseases in pediatrics and adults. We support projects from accredited academic and nonprofit research institutions and large group medical practices located anywhere in the world. Our Impact Awards support early-stage companies bringing a repurposed treatment to market.

We take an impact philanthropy approach that prioritizes patient when selecting repurposing research projects. We support both philanthropic projects, which have little or no commercial value but have critical value to patients, as well as commercial projects, which industry may bring to regulatory approval and then to market. Our proof-of-concept funding of repurposing projects allows researchers and clinicians to leverage positive data into follow-on funding.

Our current projects were selected through a two-stage submission process. Applicants submit a Letter of Intent (LOI), and the top-scoring LOIs are typically invited to submit a more detailed proposal.  Both the LOIs and proposals are reviewed by an external, volunteer Grant Review Committee which represents academia and other nonprofit research institutions, industry, clinicians and the patient/community voice. This committee helps staff and the Science Advisory Board select the strongest projects for funding. Our customized approach allows donors to be as involved in the entire process as desired.

The diversity of our current projects reflects our disease-agnostic, patient-first approach:

• more than 75% adult, less than 25% pediatric
• more than 85% clinical, less than 15% pre-clinical
• more than 75% drug, less than 25% device or other
• more than 75% US-based, less than 25% outside of the US

Current Repurposing Research Projects

*CureAccelerator Live! winner